Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Retinoid-based topical acne treatment may induce local tolerance issues such as erythema, dryness, stinging and burning sensations that may reduce adherence and efficacy.
The tested regimen (cream and cleanser) has been specifically developed to rebalance the skin microbiome and compensate side-effects of topical treatments (hydration, skin barrier repair) together with an action on skin imperfections and marks.
This open-label study was conducted in subjects aged 12 years and over with sensitive skin (>2 on a sensitivity composite score from 0-3) treated for at least one month with the fixed-dose gel combination and presenting with treatment-related skin intolerance.
The study on the evaluation of the management of side-effects of an anti-acne treatment by a cosmetic routine (cleanser and cream) following failure of the usual cosmetic routine has been conducted under dermatological control by Dermscan that is certified by the International Standards Organization (ISO) 9001-2015.
Each study report is subjected to a quality inspection by a proofreader member of Dermscan not involved in the audited study. The inspection of the study report allows to confirm that the results reflect exactly the study raw data and that the study fulfills any standard and regulatory requirements.
Regarding the statistical analysis, data obtained for each parameter, at each measurement time and on each zone are presented in raw value tables. The tables also show the descriptive statistics: means, medians, minima, maxima, standard errors of the means (SEM), confidence intervals of 95% (CI 95%) of these values as well as the variations and percentage variations. They also present the results of the statistical analysis.
Participants have the right to exit from the study at any time and for any motive in compliance with the Helsinki Declaration (1964) and its successive updates. The investigator can also interrupt the subject participation in the study prematurely in the case of a disease occurrence, a pregnancy or the occurrence of an adverse reaction.
The personnel in charge of the study collects data into individual case report forms in electronic or paper format and/or directly from measurement software. When information is collected in paper format, the double data entry is then done from these supports by the designed operator(s), without any interpretation, in specific EXCEL databases. The Project Manager or assistant checks the double data entry by comparing both databases. Then the coherence of the whole data set is checked as well as formulas used in the EXCEL tables (calculation formulas, selected data…). When all the controls are done, the database is locked.
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| change in comedogenic potential | counting of retentional and inflammatory elements on the whole face. Descriptive statistics are done in order to determine the variation significance. | from baseline to Day28 |
| change in Global Evaluation Acne (GEA) score | The dermatologist realizes clinical score on the face using the Investigator Global Acne Severity Score : from 0 Clear. No lesions to 5 Very severe. | from baseline to Day28 |
| Measure | Description | Time Frame |
|---|---|---|
| change in sensitivity score by the dermatologist | evaluation of the parameters erythema, dryness, desquamation on a 0-3 scale | from baseline to Day28 |
| change in sensitivity score by the participant (composite score) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
pregnant or nursing woman or woman planning a pregnancy during the study
cutaneous pathology on the studied zone other than acne (eczema etc.)
• use of topical or systemic treatment during the previous weeks liable to interfere with the assessment of the cutaneous acceptability of the study product (according to the investigator's appreciation, except the anti-acne treatment Epiduo and former cosmetic routine)
oral treatment of retinoids during the six previous months of the study
any change in hormonal treatment (including contraceptive) during the three previous months of the study or subject under Androcur® generic) treatments since less than six months
professional facial care during the study or within the previous month
subject manipulating her/ his acne lesions
excessive exposure to sunlight or UV-rays within the previous month
Not provided
Not provided
Not provided
participants with a failed anti-acne routine meeting the inclusion and exclusion criteria and agreeing to the study constraints
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Anna Czermanska | Eurofins | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Studio Dermatologia i Kosmetyka | Malbork | Poland |
Not provided
| ID | Term |
|---|---|
| D000152 | Acne Vulgaris |
| ID | Term |
|---|---|
| D017486 | Acneiform Eruptions |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D012625 | Sebaceous Gland Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
evaluation of the parameters itching, tightness, burning sensation on a 0-3 scale
| from baseline to Day28 |
| change in global tolerance score by the dermatologist | evaluation of the tolerance on a 0-3 scale | from baseline to Day28 |
| change in global tolerance score by the participant | evaluation of the tolerance on a 0-3 scale | from baseline to Day28 |
| change in overall effectiveness score by the dermatologist | evaluation of the effectiveness on a 0-3 scale | from baseline to Day28 |
| change in overall effectiveness score by the participant | evaluation of the effectiveness on a 0-3 scale | from baseline to Day28 |
| change in quality of life | Cardiff Acne Disability Index (CADI) questionnaire with 5 questions | from baseline to Day28 |